After selling Mazza, it became clear that our expertise was needed in a new area. Ben Lightburn, Filament Health’s CEO and Co-Founder, took note of the growing global mental health crisis. He believed that psychedelics could help, and that natural psychedelics would be the preferred choice.
Ben also recognized his unique position - he had the skills and experience to develop natural psychedelic drugs. Ben and co-founders Tom Kineshanko and Joel Sherlock combined their background as entrepreneurs with the botanical extraction expertise of the former Mazza Innovation team to bring Filament Health to the world.